Literature DB >> 22184331

Angiotensin-(1-9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor.

Monica Flores-Munoz1, Lorraine M Work, Kirsten Douglas, Laura Denby, Anna F Dominiczak, Delyth Graham, Stuart A Nicklin.   

Abstract

The renin-angiotensin system regulates cardiovascular physiology via angiotensin II engaging the angiotensin type 1 or type 2 receptors. Classic actions are type 1 receptor mediated, whereas the type 2 receptor may counteract type 1 receptor activity. Angiotensin-converting enzyme 2 metabolizes angiotensin II to angiotensin-(1-7) and angiotensin I to angiotensin-(1-9). Angiotensin-(1-7) antagonizes angiotensin II actions via the receptor Mas. Angiotensin-(1-9) was shown recently to block cardiomyocyte hypertrophy via the angiotensin type 2 receptor. Here, we investigated in vivo effects of angiotensin-(1-9) via the angiotensin type 2 receptor. Angiotensin-(1-9) (100 ng/kg per minute) with or without the angiotensin type 2 receptor antagonist PD123 319 (100 ng/kg per minute) or PD123 319 alone was infused via osmotic minipump for 4 weeks into stroke-prone spontaneously hypertensive rats. We measured blood pressure by radiotelemetry and cardiac structure and function by echocardiography. Angiotensin-(1-9) did not affect blood pressure or left ventricular mass index but reduced cardiac fibrosis by 50% (P<0.01) through modulating collagen I expression, reversed by PD123 319 coinfusion. In addition, angiotensin-(1-9) inhibited fibroblast proliferation in vitro in a PD123 319-sensitive manner. Aortic myography revealed that angiotensin-(1-9) significantly increased contraction to phenylephrine compared with controls after N-nitro-l-arginine methyl ester treatment, an effect abolished by PD123 319 coinfusion (area under the curve: angiotensin-(1-9) N-nitro-l-arginine methyl ester=98.9±11.8%; control+N-nitro-l-arginine methyl ester=74.0±10.4%; P<0.01), suggesting that angiotensin-(1-9) improved basal NO bioavailability in an angiotensin type 2 receptor-sensitive manner. In summary, angiotensin-(1-9) reduced cardiac fibrosis and altered aortic contraction via the angiotensin type 2 receptor supporting a direct role for angiotensin-(1-9) in the renin-angiotensin system.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22184331     DOI: 10.1161/HYPERTENSIONAHA.111.177485

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  32 in total

1.  Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2.

Authors:  Minghao Ye; Jan Wysocki; Francisco R Gonzalez-Pacheco; Mahmoud Salem; Karla Evora; Laura Garcia-Halpin; Marko Poglitsch; Manfred Schuster; Daniel Batlle
Journal:  Hypertension       Date:  2012-07-09       Impact factor: 10.190

Review 2.  Update on the angiotensin AT(2) receptor.

Authors:  Claudia A McCarthy; Robert E Widdop; Kate M Denton; Emma S Jones
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

Review 3.  Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure.

Authors:  Vaibhav B Patel; Jiu-Chang Zhong; Maria B Grant; Gavin Y Oudit
Journal:  Circ Res       Date:  2016-04-15       Impact factor: 17.367

4.  Sex differences in angiotensin-converting enzyme modulation of Ang (1-7) levels in normotensive WKY rats.

Authors:  Kanchan Bhatia; Margaret A Zimmerman; Jennifer C Sullivan
Journal:  Am J Hypertens       Date:  2013-01-27       Impact factor: 2.689

5.  PI3K/AKT signaling pathway plays a role in enhancement of eNOS activity by recombinant human angiotensin converting enzyme 2 in human umbilical vein endothelial cells.

Authors:  Yan Zhang; Shi-Jie Wang; Zhen-Hua Han; Yong-Qin Li; Jia-Hong Xue; Deng-Feng Gao; Xiao-San Wu; Cong-Xia Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

6.  Differences in angiotensin (1-7) between men and women.

Authors:  Jennifer C Sullivan; Paula Rodriguez-Miguelez; Margaret A Zimmerman; Ryan A Harris
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-06       Impact factor: 4.733

Review 7.  Effects of apelin on the cardiovascular system.

Authors:  Anna Folino; Pier Giorgio Montarolo; Michele Samaja; Raffaella Rastaldo
Journal:  Heart Fail Rev       Date:  2015-07       Impact factor: 4.214

8.  RAS-Mediated Adaptive Mechanisms in Cardiovascular Tissues: Confounding Factors of RAS Blockade Therapy and Alternative Approaches.

Authors:  Rukhsana Gul; Maya Ramdas; Chirag H Mandavia; James R Sowers; Lakshmi Pulakat
Journal:  Cardiorenal Med       Date:  2012-10-27       Impact factor: 2.041

9.  Angiotensin-(1-9) prevents cardiomyocyte hypertrophy by controlling mitochondrial dynamics via miR-129-3p/PKIA pathway.

Authors:  Cristian Sotomayor-Flores; Pablo Rivera-Mejías; César Vásquez-Trincado; Camila López-Crisosto; Pablo E Morales; Christian Pennanen; Iva Polakovicova; Víctor Aliaga-Tobar; Lorena García; Juan Carlos Roa; Beverly A Rothermel; Vinicius Maracaja-Coutinho; Hung Ho-Xuan; Gunter Meister; Mario Chiong; María Paz Ocaranza; Alejandro H Corvalán; Valentina Parra; Sergio Lavandero
Journal:  Cell Death Differ       Date:  2020-03-09       Impact factor: 15.828

10.  Adenoviral delivery of angiotensin-(1-7) or angiotensin-(1-9) inhibits cardiomyocyte hypertrophy via the mas or angiotensin type 2 receptor.

Authors:  Monica Flores-Muñoz; Bruno M D C Godinho; Abdulaziz Almalik; Stuart A Nicklin
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.